Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

centerforbiosimilars.com image

News from centerforbiosimilars.com

All of today’s top news stories from centerforbiosimilars.com. Get the full analysis behind how media bias impacts breaking news.

Ground News has come across 64 headlines reported on by centerforbiosimilars.com during the past 3 months.

Ground News rates centerforbiosimilars.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

centerforbiosimilars.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about centerforbiosimilars.com

Where is centerforbiosimilars.com located?centerforbiosimilars.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top centerforbiosimilars.com News

Biocon's Breakthrough: Yesafili Gets Green Light in Canada

Health Canada · Toronto

Biocon's Breakthrough: Yesafili Gets Green Light in Canada

67% Left coverage: 9 sources

Biocon Biologics has received Health Canada's approval for Yesafili, a biosimilar injection for eye ailments. As the first Eylea biosimilar approved in Canada, Yesafili's launch is set for July 4, 2025. This milestone highlights Biocon's commitment to affordable, high-quality biologics worldwide.See the Story

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Australia · Australia

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.See the Story

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.Read Article

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.See the Story

Adalimumab Double Take: The Unexpected Return to Reference Humira

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.Read Article

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

CT-P39, an omalizumab biosimilar, shows comparable efficacy and safety to the original in treating chronic spontaneous urticaria, enhancing patient access.Read Article

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and patient safety in biosimilars.United States · United States Read Article

Expanding Access to Generics and Biosimilars Could Help Reduce Rising Medication Costs

A recent opinion piece has highlighted the potential be […] The post Expanding Access to Generics and Biosimilars Could Help Reduce Rising Medication Costs first appeared on GeneOnline News. The post Expanding Access to Generics and Biosimilars Could Help Reduce Rising Medication Costs appeared first on GeneOnline News.Pharma · United States See the Story

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

Tocilizumab biosimilar CT-P47, administered via autoinjector, offers comparable efficacy and a consistent safety profile to reference tocilizumab in patients with rheumatoid arthritis.Read Article

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes for patients who have type 2 diabetes.Fredericton · Fredericton See the Story

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.Germany · Germany Read Article

Breaking News Topics Related to centerforbiosimilars.com